mTOR/AMPK regulation of cellular recycling — rapamycin-like mTOR inhibition and metformin-like AMPK activation
Autophagy ("self-eating") is the process by which cells identify, engulf, and break down their own damaged components — misfolded proteins, dysfunctional mitochondria, ruptured lysosomes — inside double-membrane vesicles called autophagosomes. The resulting cargo is delivered to lysosomes for degradation, and the recovered building blocks (amino acids, lipids, sugars) are recycled back into the cytoplasm. This is a baseline, constantly-running housekeeping process, not an emergency response only — though its rate is tightly tuned by nutrient and energy signals.
Cells continuously accumulate wear-and-tear: oxidized proteins misfold and aggregate, mitochondria lose membrane potential and leak reactive oxygen species, and damaged organelles can no longer perform their functions. Left unaddressed, this debris interferes with normal cell function and can trigger inflammatory or stress signaling.
Autophagy addresses this through a staged sequence: initiation (nucleation of an isolation membrane, the phagophore), elongation (the membrane wraps around targeted cargo), closure (a mature double-membrane autophagosome forms), and fusion with a lysosome (delivering acid hydrolases that degrade the contents into reusable building blocks).
This simulator treats autophagy induction and cellular debris burden as adjustable, illustrative parameters — the animation is a simplified conceptual model of autophagosome formation and cargo degradation, not a quantitative prediction of any individual cell's biology.
Because autophagic capacity tends to decline with age while cellular damage tends to accumulate, the balance between debris production and its clearance is a recurring theme across the later stages of this simulation — set by the two sliders in the control panel.
Mechanistic target of rapamycin complex 1 (mTORC1) integrates signals about amino acid availability, growth factors, and cellular energy status. When nutrients are abundant, mTORC1 is active at the lysosomal surface and phosphorylates the ULK1 initiation complex in a way that keeps it inactive — suppressing autophagosome formation. Under these nutrient-replete conditions, the cell's resources are directed toward growth, protein synthesis, and proliferation rather than self-degradation.
mTORC1 acts as the cell's central growth-versus-recycling switch. In the model shown here, when the pathway modulator is set to "None," the mTORC1 complex at the top of the cell lights up and an inhibitory signal (amber bar) is drawn toward the autophagy machinery — representing suppressed autophagosome formation. Debris still accumulates but is cleared only slowly.
Biologically, active mTORC1 phosphorylates ULK1 at an inhibitory site, preventing the ULK1-ATG13-FIP200 initiation complex from triggering phagophore nucleation. mTORC1 also phosphorylates transcription factors (e.g., TFEB) to keep them in the cytoplasm, reducing transcription of lysosomal and autophagy genes.
This is an adaptive, not pathological, state under normal nutrient-rich conditions — but the same suppression, if sustained together with rising cellular damage, is the mechanistic backdrop for interventions explored in later stages.
This baseline "nutrient-rich, mTOR-active" condition is the reference state against which mTOR inhibition (Stage 3) and AMPK activation (Stages 4–5) are compared in the live metrics panel.
Rapamycin (and related rapalogs) binds the intracellular protein FKBP12; the resulting complex docks onto mTORC1 and inhibits its kinase activity. With mTORC1 signaling suppressed, its inhibitory phosphorylation of the ULK1 complex is relieved, autophagosome nucleation proceeds more readily, and autophagic flux increases — even though no genuine nutrient-scarcity signal has occurred. This is a pharmacological route to autophagy induction that bypasses the need for actual caloric restriction.
When the pathway modulator is set to the mTOR-inhibitor option, small violet hexagons (representing rapamycin) drift in from outside the cell and bind the mTORC1 complex, dimming the amber suppression signal that was active in Stage 2. With the brake released, the illustrative autophagosome-formation rate rises — visualized as more frequent double-membrane vesicles forming around debris and converting into autolysosomes (teal).
In the live metrics, this shift is reflected as the "Autophagy activity" tile moving from Suppressed to Enhanced, an increase in the illustrative debris clearance rate, and a "Pathway mechanism" reading of mTOR inhibition. Whether the resulting clearance is adequate depends on how much debris burden is set on the second slider — with elevated burden, clearance may still lag if the underlying damage-production rate is high.
This simplified model does not represent rapamycin pharmacokinetics, dosing regimens, or off-target effects (e.g., on mTORC2); it illustrates only the qualitative direction of the mTORC1-autophagy relationship.
Because rapamycin acts pharmacologically rather than through an actual energy-stress signal, it can induce autophagy in cells that are otherwise well-nourished — a distinguishing feature from the AMPK-mediated route explored next.
AMP-activated protein kinase (AMPK) is the cell's principal energy-status sensor, activated when the AMP:ATP and ADP:ATP ratios rise — signaling that energy is becoming scarce. Once active, AMPK directly phosphorylates and activates the ULK1 initiation complex (at sites distinct from those targeted by mTORC1) and also inhibits mTORC1 itself via TSC2 and Raptor phosphorylation. The result is a pathway that promotes autophagy through energy-stress sensing rather than through nutrient-abundance sensing alone.
In the simulation, setting the pathway modulator to the AMPK-activator option lights up the AMPK complex at the base of the cell, drawing a cyan activation arrow toward the autophagy machinery — the mirror image of the mTOR suppression signal seen in Stage 2. The illustrative autophagosome formation rate increases similarly to the rapamycin case, but through a mechanistically distinct route.
AMPK activation is triggered by conditions that genuinely reduce cellular ATP availability — exercise, caloric restriction, hypoxia, or glucose deprivation — as well as by certain pharmacological agents. Because AMPK both activates ULK1 directly and relieves mTORC1-mediated suppression, it engages autophagy through two reinforcing arms simultaneously.
This stage sets up the mechanistic foundation for Stage 5, which examines a specific pharmacological AMPK activator — metformin — and how it triggers this same energy-sensing pathway without requiring actual systemic energy deprivation.
AMPK and mTOR act as reciprocal, cross-regulating nodes: AMPK activation both stimulates ULK1 directly and suppresses mTORC1, making energy-stress signaling and nutrient-abundance signaling converge on the same downstream initiation complex.
Metformin, widely used for glycemic control, is understood to mildly inhibit mitochondrial Complex I of the electron transport chain. This partial inhibition reduces cellular ATP production, raising the AMP:ATP ratio; the LKB1 kinase then phosphorylates and activates AMPK. Once active, AMPK promotes autophagy through the same ULK1-activating and mTORC1-inhibiting mechanisms described in Stage 4 — giving metformin a pharmacological path to autophagy stimulation that is mechanistically distinct from, but complementary to, direct mTOR inhibitors like rapamycin.
When the pathway modulator is set to the AMPK-activator option in this stage, teal diamond molecules (representing metformin) drift toward the mitochondrion icon in the cell rather than directly toward the AMPK complex — depicting the indirect mechanism: metformin engages mitochondrial Complex I first, and the resulting shift in cellular energy charge is what ultimately activates AMPK.
This two-step chain (drug → mitochondrial Complex I → AMP:ATP ratio → LKB1 → AMPK → ULK1) distinguishes metformin's route to autophagy induction from rapamycin's direct binding to mTORC1. Both converge on increased illustrative debris clearance in the live metrics panel, but they represent mechanistically independent — and in principle combinable — pharmacological strategies.
As in earlier stages, whether the resulting clearance rate is labeled "Adequate" or "Inadequate" depends on the debris-burden slider: a high burden of accumulated cellular damage can still outpace even an enhanced clearance rate, illustrating that pathway activation alone does not guarantee that clearance will keep up with the damage being generated.
This simulation presents a simplified, conceptual/illustrative model of mTOR and AMPK signaling and their relationship to autophagy for educational purposes — it does not represent a validated quantitative or clinical model of any specific drug, dose, or patient outcome.